TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Pain and quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean duration of surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: hip flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: internal rotation of the preferred kicking leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: positive provocative hip tests
Endpoint domain: Adverse events/effects
Primary endpoint: mean hallucination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Abdominal pain/cramps
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients reporting no back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of back and leg pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Japanese Orthopedic Association function scores (JOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of cerebral desaturation time to total cardiopulmonary bypass time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAED score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative mean anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of invasive breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of invasive estrogen receptor (ER)-positive tumors
Endpoint domain: Mortality/survival
Primary endpoint: left ventricular diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dietary behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: adolescent substance abuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CABG rates at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: minor bleeding rates at 1 year
Endpoint domain: Adverse events/effects
Primary endpoint: IC improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in FRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fatigue Severity Scale reduction
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: combined cardiovascular end-point of death, re-infarction or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Total operative room occupation time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of disposable materials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of development of heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: satisfaction with postoperative pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative supplemental analgesic rescue use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severe asthma exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: Serious asthma-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of gastric tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time required for gastric tube placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hospitalizations and ED visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Air-bone gap closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility and acceptability of telephone assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time for adequate sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of sedation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean plasma propofol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to orientation for name and place
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean SFx value at resumption of spontaneous ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eccentric and isometric moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stretch tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tendon stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immediate axillary odor reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intent to conceive
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Colonoscopy participation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of myoclonus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Effective contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuation rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: M1:M2 concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PWD quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: caregiver depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Repeat hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance on the posttest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with educational innovation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: subnormal cortisol response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Canadian Cardiovascular Society classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of angina attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Deaths from CHD
Endpoint domain: Mortality/survival
Primary endpoint: Nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: neurophysiological function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HZ/su vaccine response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-glycoprotein E GMCControl/Coadmin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of hot flushes/night sweats per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24-h systolic and diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Circadian BP rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum bicarbonate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Free Fatty Acids (FFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean serum HMW adiponectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in number of subjects prematurely terminated due to severe symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Decreases in rhinorrhea and nasal blockage scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Suppression of plasma thymus- and activation-regulated chemokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional thyroid capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CNR between infarct and blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transmural extent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skin Blood Flow (SBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of acrophobia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttreatment skin conductance fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical global improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Active disease at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-diastolic velocity of central retinal artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postvaccination geometric mean titers against influenza A viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: seroprotection against influenza A/H1N1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: seroconversion against A/H3N2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pathological complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: distension volume required to induce discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 28-day survival benefit
Endpoint domain: Mortality/survival
Primary endpoint: Risk of developing CNV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEDAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intake of omega-3 fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: RBCM fatty acid composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decline in bowel quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rectal bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Overall bowel problems
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically significant PDAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right ventricle pressure/systolic arterial pressure ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Earlier extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of subjects remaining well
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in visual and/or functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: No polypoidal lesions with leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotective Rate (SPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentration (GMC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: All-cause treatment discontinuation rates
Endpoint domain: Mortality/survival
Primary endpoint: Plasma BNP levels (ng/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Undetectable trough serum levels of infliximab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of American College of Rheumatology (ACR) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum C-reactive protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response variability after concussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean time of maximum plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC(0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolongation of brain sparing to delivery interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain following supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Block success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung function (forced expiratory volume in 1s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clearance of parasitaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Feasibility of SR imaging with IV contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in SR and epsilon measurements with contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ocular salvage
Endpoint domain: Mortality/survival
Primary endpoint: vitreous seed recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subretinal seed recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return of normal urodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUA score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dimensional stability of pontic sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cold pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(last) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(∞) ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of pelvic floor disorders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: grade 3-4 thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: severe mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Total Body Fat (TBF) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Waist Circumference (WC) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TC/HDL-C ratio improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of necrotic tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of exudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean plasma total DHA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma volume decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lean mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pneumococcal vaccination rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rate
Endpoint domain: Adverse events/effects
Primary endpoint: Shoulder morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking urge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking lapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for skin grafting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: desflurane concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: recovery times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gene expression of FAT/CD36 and beta-HAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gene abundance of FAT/CD36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: long-term clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythrocyte GPx activity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in verbal fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Improvements in constructional praxis
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: flap skin blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: EBM knowledge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in TWSTRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (dysphagia and dry mouth)
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of EGD examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for second EGD
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: UPDRS II improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS III improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confirmed EDSS worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new lesion activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for e-diary
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Analysis time of diary
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seropositivity persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in serum urate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median reduction in tophus area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gout flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: Reinfarction rates
Endpoint domain: Physiological/clinical
Primary endpoint: Rectal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of CT simulation rescans
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Serum IGF-1 level improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of IL-6 and TNF-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cancer cell involvement around pelvic autonomic nerves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Metastatic nodes location
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Running performance (T)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Running performance (C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P-VASP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: time to disease progression
Endpoint domain: Mortality/survival
Primary endpoint: quality of life variables
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Affect regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower relapses in six months
Endpoint domain: Mortality/survival
Primary endpoint: Successful message receipt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of message format
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to clinic at requested time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of AMI
Endpoint domain: Mortality/survival
Primary endpoint: Risk of fatal AMI
Endpoint domain: Mortality/survival
Primary endpoint: mean change from baseline in the number of toilet voids/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median change from baseline in the number of UUI episodes/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of histology for low-grade dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of histology for absence of dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes